Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)